Pharmacotherapy in the Treatment of Obesity
| Autor: | Simona Negreș, Oana Cristina Șeremet, Cornel Chiriță, Floriana Elvira Ionică |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty lcsh:Specialties of internal medicine business.industry medicine.disease diethylpropion Obesity 03 medical and health sciences 030104 developmental biology Pharmacotherapy lcsh:RC581-951 anti-obesity pharmacotherapy phentermine/topiramate Endocrinology diabetology Medicine business Intensive care medicine lorcaserin orlistat |
| Zdroj: | Romanian Journal of Diabetes Nutrition and Metabolic Diseases, Vol 23, Iss 4, Pp 415-422 (2016) |
| ISSN: | 2284-6417 |
| DOI: | 10.1515/rjdnmd-2016-0048 |
| Popis: | Background and Aims: In the last three decades, obesity and its related co morbidities has quickly increased. Sometime, obesity was viewed as a serious health issue in developed countries alone, but now is recognized as a worldwide epidemic, and its associated costs are enormous. Obesity is related with various diseases, like hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, chronic cardiovascular diseases, respiratory conditions, alongside chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review purpose is to provide data on the current anti-obesity drugs, also available and in the development. Material and Methods: We searched MEDLINE from 2006 to the present to collect information on the anti-obesity pharmacotherapy. Results and Conclusions: In the patients with obesity related comorbidities, there may be an adaptation of the anti-obesity pharmacotherapy to the patients’ needs, in respect to the improvements of the cardiometabolic parameters. Although their efficacy was proven, the anti-obesity pharmacotherapies have presented adverse events that require a careful monitoring during treatment. The main obstacle for approve new drugs seems to be the ratio between the risks and the benefits, because of a long-time background of perilous anti-obesity drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|